FIBRICOR® significantly improves all cholesterol parameters, including triglycerides, total cholesterol, LDL-C, and HDL-C1
FIBRICOR is effective adjunctive therapy to diet in patients with severe hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia1
Indications and Usage
FIBRICOR (fenofibric acid) is indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia (≥500 mg/dL). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides > 2000 mg/dL may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
Primary Hypercholesterolemia or Mixed Dyslipidemia
FIBRICOR is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia.
Important Limitations of Use
Fenofibrate at a dose equivalent to 105 mg of FIBRICOR was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.
- FIBRICOR [prescribing information]. Athens, GA: Athena Bioscience, LLC.; 2019.